Abbott’s Recommitment To Core Diagnostics Is Rewarded By Strong Returns
This article was originally published in The Gray Sheet
Executive Summary
Abbott has a newfound loyalty to its long-struggling core diagnostics business, which the company was at the brink of unloading just last year, and the division has responded with a dramatic turnaround